Research programme: Alzheimer's disease vaccine - ID Pharma/Eisai
Latest Information Update: 14 Dec 2015
At a glance
- Originator DNAVEC Corporation; Eisai Co Ltd
- Developer Eisai Co Ltd; ID Pharma
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 13 Apr 2006 Preclinical trials in Alzheimer's disease in Japan (unspecified route)